DS
BEAM icon

David Shaw’s Beam Therapeutics BEAM Stock Holding History

David Shaw’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,000
Closed -$1.6M – 4749
2021
Q1 		$1.6M Buy
+20,000
New +$1.9M ﹤0.01% 2773

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

David Shaw's BEAM Position: Q2 2026 in Review

David Shaw opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 130,577 shares worth $4.48M. The stake represents ﹤0.01% of the portfolio and ranks #2494 among its holdings. This is a return to the name: David Shaw previously reported a position in BEAM as recently as Q4 2025.

David Shaw first reported a position in BEAM in Q1 2021 and has held it in 7 quarters since. The position peaked at $5.16M in Q3 2021. 276 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • David Shaw held 130,577 shares of Beam Therapeutics worth $4.48M as of Q2 2026.
  • Beam Therapeutics was a new David Shaw position in Q2 2026.
  • Beam Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2494 holding.
  • David Shaw first reported a position in Beam Therapeutics in Q1 2021 and has held it in 7 quarters since.
  • David Shaw's Beam Therapeutics position peaked at $5.16M in Q3 2021.
  • 276 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.